Faricimab is contraindicated in patients with: ocular or periocular infections; active intraocular inflammation; a known hypersensitivity to faricimab or any of its excipients. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation.
- TRADE NAME: Vabysmo (Genentech)
- INDICATIONS:
1. Neovascular (wet) age-related macular degeneration. 2. Diabetic macular edema.
- CLASS: Angiopoietin-2 inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 7.5 days (estimated)
- FDA APPROVAL DATE: 01/28/2022
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: No adequate and well-controlled studies of faricimab administration in pregnant women..
- See adverse reactions attributed to class:
Vascular endothelial growth factor (VEGF) inhibitor / antagonist
Please login to view the rest of this drug profile.
Page last updated 07/24/2024
